RSS

golimumab

A label change for MSD’s (known as Merck in the US and Canada) ulcerative colitis (UC) treatment — SIMPONI (golimumab) — has received approval from the European Commission. more

News

Real-world data presented by Merck have demonstrated the long-term clinical effectiveness of golimumab (Simponi) for the treatment of rheumatic diseases. more

News